Cytokine therapy for metastatic renal cell carcinoma

Seminars in Urologic Oncology

Volumn 19, Issue 2, 2001, Pages 148-154

  Bukowshi, R M ^a  

^a NONE   (United States)

Author keywords

Cytokine therapy; Renal cell carcinoma

Indexed keywords

MEDROXYPROGESTERONE ACETATE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; TAMOXIFEN; VINBLASTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREGULATION; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; META ANALYSIS; METASTASIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; KIDNEY NEOPLASMS;

EID: 0035048096     PISSN: 10810943     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. A phase 2 study of surveillance in patients with metastatic renal cell carcinoma and assessment of response of such patients to therapy on progression
2. Characterization of TIL subsets from human renal carcinoma: Specific reactivity defined by cytotoxicity, IFNγ secretion, and proliferation
3. The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma
4. Interferon gamma-1b compared with placebo in metastatic renal cell carcinoma
5. Renal cell carcinoma: Antitumor effects of leukocyte interferon
6. Interferon-alpha in malignant and viral diseases: A review
7. The treatment of renal cell carcinoma with human leukocyte alpha-interferon
8. Clinical practice guidelines: Renal cell carcinoma
9. Interferon alpha 2-a in advanced renal cell carcinoma: Treatment results and survival in 159 patients with long-term follow-up
10. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer
11. Interferon-α and survival in metastatic renal cell carcinoma: Early results of randomized trial
12. Cytoreduction nephrectomy in metastatic renal cancer: The results of Southwest Oncology Group trial 8949
13. Phase I study of polyethylene glycol I (PEG) interferon alpha-2b (PEG Intron) in patients with solid tumors
14. Selective in vitro growth of T-lymphocytes from normal bone marrows
15. Interleukin-2, autotolerance and autoimmunity
16. Natural history and therapy of metastatic renal cell carcinoma: Role of interleukin-2
17. Low-dose interleukin-2
18. Results of treatment of 255 patients with metastatic renal cell carcinoma who receive high dose recombinant interleukin-2 therapy
19. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic RCC: An interim report
20. A comparison of 2 modes of administration of recombinant interleukin-2: Continuous intravenous infusion alone versus subcutaneous administration plus interferon alfa in patients with advanced RCC
21. Recombinant human interleukin-2, recombinant interferon alfa-2a, or both in metastatic renal cell carcinoma
22. Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha
23. A progress report on the outpatient treatment of patients with advanced renal cell carcinoma using subcutaneous recombinant interleukin-2
24. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer
25. Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma: Six years of experience
26. A phase I study including pharmacokinetics of polyethylene glycol conjugated interleukin 2
27. Interactive effects of α-interferon A/D and interleukin-2 on murine lymphokine-activated killer activity: Analysis at the effector and precursor level
28. Recombinant interleukin-2, recombinant interferon alfa-2a or both in metastasis renal cell carcinoma
29. Survival in renal cell carcinoma - A randomized evaluation of tamoxifen vs interleukin-2, α-interferon (leukocyte) and tamoxifen
30. Phase I trial of recombinant granulocyte-macrophage colony stimulating factor in lung cancer patients: Clinical and immunologic effects
31. Phase II trial of subcutaneously administered granulocyte-macrophage colony stimulating factor in patients with metastatic renal cell carcinoma
32. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin-2, and interferon α in progressive metastatic melanoma and renal cell carcinoma
33. Combined immunotherapy with subcutaneous GM-CSF, low-dose IL-2, and IFNα can induce complete remission in metastatic renal cell carcinoma
34. Recombinant interferon alpha plus vinblastine in metastasis renal cell cancer: Updated results
35. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: Results of a European multi-center phase III study
36. Interleukin-2 based home therapy of metastatic renal cell carcinoma: Risks and benefits in 215 consecutive single institution patients
37. Risk and long-term outcome in metastatic renal cell carcinoma patients receiving SC interleukin-2, SC interferon-alfa 2A, and IV 5-fluorouracil
38. Results of a randomized clinical trial comparing SC interleukin-2, SC alpha-2a-interferon, and IV bolus 5-fluorouracil against oral tamoxifen in progressive metastatic renal cell carcinoma patients
39. Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: A multicenter phase II trial
40. Phase II trial of 5-fluorouracil, interferon-α and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma
41. Randomized study of interleukin-2 (IL-2) and interferon (IFN) with or without 5-FU (FUCY study) in metastatic renal cell carcinoma (MRCC)
42. Interleukin-2 based therapy for metastatic renal cell cancer: The Cytokine Working Group experience, 1989-1997
43. Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: Results of a sequential nonrandomized phase II study
44. Cytokine combinations: Therapeutic use in patients with advanced renal cell carcinoma
45. Renal cell carcinoma metastatic to the lung: Potential benefit in the combination of biological therapy and surgery
46. Characterization of TIL subsets from human renal carcinoma: Specific reactivity defined by cytotoxicity, IFNγ secretion and proliferation
47. Signal transduction abnormalities in T-lymphocytes from patients with advanced renal cell carcinoma: Clinical relevance and effects of cytokine therapy